drugset
drugset / Trial / NCT03374228

A Study to Evaluate the Bioavailability of BMS-986205

NCT03374228 ↗

Phase 1 Completed 7 enrolled Bristol-Myers Squibb
NaSingle-groupOpen-labelOther

Summary

Assess the absolute bioavailability of a tablet formulation of BMS-986205 following simultaneous oral administration of BMS-986205 and intravenous infusion of \[13C\]BMS-986205 solution for intravenous administration in healthy participants.

Timeline

Start
2018-01-04
Primary completion
2018-02-16
Completion
2018-02-16

Drugs

EvaluationDrugModalityDoseRoute
Subject LINRODOSTAT Small molecule — —

Indications

No indication recorded.